AZN.L - AstraZeneca PLC

LSE - LSE Delayed price. Currency in GBp
Show:
Income statement
Balance sheet
Cash flow
Annual
Subscribe to Premium to download historical data

Income statement

Currency in USD. All numbers in thousands
Breakdown
ttm
31/12/2019
31/12/2018
31/12/2017
31/12/2016
Total revenue
24,384,000
24,384,000
22,090,000
22,465,000
23,002,000
Cost of revenue
4,921,000
4,921,000
4,936,000
4,318,000
4,126,000
Gross profit
19,463,000
19,463,000
17,154,000
18,147,000
18,876,000
Operating expenses
Research development
6,059,000
6,059,000
5,932,000
5,757,000
5,890,000
Selling general and administrative
12,021,000
12,021,000
10,362,000
10,303,000
9,739,000
Total operating expenses
17,761,000
17,761,000
15,644,000
15,855,000
15,304,000
Operating income or loss
1,702,000
1,702,000
1,510,000
2,292,000
3,572,000
Interest expense
833,000
833,000
796,000
713,000
680,000
Income before tax
1,548,000
1,548,000
1,993,000
2,227,000
3,552,000
Income tax expense
321,000
321,000
-57,000
-641,000
146,000
Income from continuing operations
1,227,000
1,227,000
2,050,000
2,868,000
3,406,000
Net income
1,335,000
1,335,000
2,155,000
3,001,000
3,499,000
Net income available to common shareholders
1,335,000
1,335,000
2,155,000
3,001,000
3,499,000
Basic EPS
-
-
1.70
2.37
2.77
Diluted EPS
-
-
1.70
2.37
2.76
Basic average shares
-
-
1,267,000
1,266,000
1,265,000
Diluted average shares
-
-
1,267,000
1,267,000
1,266,000
EBITDA
-
6,143,000
6,542,000
5,976,000
6,589,000
By using Yahoo, you agree that we and our partners can use cookies for purposes such as customising content and advertising. See our Privacy Policy to learn more